Pharma Veterans

  Can Money Buy Happiness?  – Asrar Qureshi’s Blog Post #1263 Dear Colleagues! This is Asrar Qureshi’s Blog Post #1263 for Pharma Veterans. Pharma Veterans Blogs are published by Asrar Qureshi on its dedicated site https://pharmaveterans.com. Please email to pharmaveterans2017@gmail.com  for publishing your contributions here. Credit: Kampus Production Preamble This blog post is based on research done by Harvard Business School’s Jon M. Jachimowicz, Assistant Professor of Business Administration. Link at the end. Can Money Buy Happiness? Yes, But Not in the Way Most People Think For generations, society has repeated a familiar phrase: “Money can’t buy happiness.” It sounds wise. Moral. Comforting.  It suggests that fulfillment lies beyond material wealth and that happiness is accessible regardless of financial status. And to some extent, that is true. But modern behavioral science paints a more nuanced picture. The real answer is not a simple yes or no. It is this: “...

Heat – The New Form of Inequality – Asrar Qureshi’s Blog Post #1262 Dear Colleagues! This is Asrar Qureshi’s Blog Post #1262 for Pharma Veterans. Pharma Veterans Blogs are published by Asrar Qureshi on its dedicated site https://pharmaveterans.com. Please email to pharmaveterans2017@gmail.com  for publishing your contributions here. Credit: Tom Fisk Preamble This blog post is based on insights from an article by James Karuga. Link at the end. When Heat Becomes Inequality: How South Asia’s Cities Are Being Redefined by Extreme Temperatures Heat used to be considered a weather problem. Now it is becoming a poverty problem. In South Asia, extreme heat is no longer simply an uncomfortable seasonal event. It is increasingly a force that determines who can work, who can sleep, who can remain healthy, and in some cases, who survives. The cruel truth is this: heat does not affect everyone equally. Recent analysis highlights how heatwaves are deepening urban inequality across South Asia, tu...

Leading Change Without a Roadmap – Asrar Qureshi’s Blog Post #1261 Dear Colleagues! This is Asrar Qureshi’s Blog Post #1261 for Pharma Veterans. Pharma Veterans Blogs are published by Asrar Qureshi on its dedicated site https://pharmaveterans.com. Please email to pharmaveterans2017@gmail.com  for publishing your contributions here. Credit: Alexas fotos Preamble This blog post is based on insights from an article by Chengyi Lin and Michael Y. Lee of INSEAD. The article appeared in INSEAD Knowledge on May 6,2026. Link at the end. Leading Change Without a Roadmap: How Great Organizations Move Forward When the Path Does Not Exist Leaders love roadmaps. Roadmaps create comfort. They suggest predictability, sequence, control, and certainty. They reassure boards, calm executives, and make transformation feel manageable. But what happens when the roadmap does not exist? What happens when the challenge is so new, so complex, and so uncertain that no benchmark, no precedent, and no proven fr...

Building Psychological Safety for High Performing Teans – Asrar Qureshi’s Blog Post #1260 Dear Colleagues! This is Asrar Qureshi’s Blog Post #1260 for Pharma Veterans. Pharma Veterans Blogs are published by Asrar Qureshi on its dedicated site https://pharmaveterans.com. Please email to pharmaveterans2017@gmail.com  for publishing your contributions here. Credit: Capture View Credit: Emre Gencer Preamble This blog post is based on insights from a discussion published in the Harvard Business School, Working Knowledge, between Professor Amy C. Edmondson, and Kara Baskin. Link at the end. Harvard Business School Professor Amy C. Edmondson coined the term “team psychological safety” in the 1990s to describe work environments where candor is expected and where employees can speak up without fear of retribution. When employees feel psychologically safe, they’re empowered to iterate and take risks, leading to better team performance.   The Silent Superpower of High-Performing Teams: P...

  WHO Prequalifies First Ever Malaria Treatment for Newborns and Infants – Asrar Qureshi’s Blog Post #1259 Dear Colleagues! This is Asrar Qureshi’s Blog Post #1259 for Pharma Veterans. Pharma Veterans Blogs are published by Asrar Qureshi on its dedicated site https://pharmaveterans.com. Please email to pharmaveterans2017@gmail.com  for publishing your contributions here. Preamble The WHO prequalified Coartem Baby in April 2026 as a malaria treatment designed for infants weighing 2–5 kg (4.4–11 lb). These sweet cherry-flavored, dissolvable tablets treat acute, uncomplicated malaria, addressing a gap in neonatal care. The drug has been developed by Novartis and Medicines for Malaria Venture and is designed for distribution in high-risk areas.  The drug contains artemether and lumefantrine. The combination is not new as such; it has been in use for children and adults for many years. However, the use in newborns and infants was not qualified and relevant dosage forms were no...

Cost of Incentives to Work Life Balance – Asrar Qureshi’s Blog Post #1258 Dear Colleagues! This is Asrar Qureshi’s Blog Post #1258 for Pharma Veterans. Pharma Veterans Blogs are published by Asrar Qureshi on its dedicated site https://pharmaveterans.com. Please email to pharmaveterans2017@gmail.com  for publishing your contributions here. Credit: Ketut Subiyanto Preamble This post is based on insights taken from Harvard Business School Working Knowledge article by Ashley V. Whillans and Rachel Kim Rackza. Link at the end. When Incentives Redefine Priorities: A Pharma Industry Perspective on Bonuses, Performance, and Life The pharmaceutical industry is built on precision, compliance, and performance. From sales targets to regulatory milestones, from product launches to market share growth, everything is measured, tracked, and rewarded. And rightly so. In a high-stakes industry where outcomes impact both business and patient lives, performance matters. But beneath this structured sys...